Pharmacologic data and technical feasibility of intraperitoneal doxorubicin administration.
Seventy intraperitoneal administrations of doxorubicin were performed in 12 patients with malignant disease in the abdominopelvic space. Peritoneal and hematologic drug levels were measured by fluorimetric assay. A first-order decline in the peritoneal level was determined (T 1/2 96 +/- 18 min), with a mean drug absorption of 84% in 4 h (range 40-96%) and a mean ratio of a peak dialysate/peak serum level of 111 (range 12-390). Gastrointestinal toxicity was common and peritoneal phlogosis occurred twice. The doxorubicin level and the time of peritoneal exposure seem to be critical factors for major local toxicity. At a moderate concentration doxorubicin can be intraperitoneally administered, but its usefulness is probably confined to patients with minimal abdominal disease.
D000008:Abdominal Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary; D000042:Absorption; D000328:Adult; D000368:Aged; D001202:Ascitic Fluid / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism*; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007700:Kinetics; D008207:Lymphatic Metastasis; D008875:Middle Aged; D010386:Pelvic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary; D013997:Time Factors
D004317:Doxorubicin